Media.Player

Treatment of breast cancer using a combination of cholesterol synthesis inhibitors and estrogen receptor ligands

Detailed Technology Description

None

Others

*Abstract

We have found that certain cholesterol synthesis inhibitors potently reduce the growth of breast cancer cells. While conducting studies to examine the molecular mechanisms behind this phenomenon, we determined that cholesterol synthesis inhibitors induced the anti-proliferative protein, estrogen receptor (ER)b, in both ERa-positive and ERa-negative breast cancer cell lines, including triple negative cells. These cholesterol synthesis inhibitors also abolished pro-proliferative ERa in ERa-positive breast cancer cells. Since ERb is known to inhibit the proliferation of breast cancer cells, we administered a combination of cholesterol synthesis inhibitor and ERb agonist to determine whether such a regimen might prove more effective in killing breast cancer. Our findings show that the combination effectively arrested the growth of breast cancer cells.POTENTIAL AREAS OF APPLICATION:• Treatment of breast cancer and especially useful for triple negative tumor typesMAIN ADVANTAGES OF INVENTION:• Induction an anti-proliferative receptor in breast cancer cells• Blocks proliferation of breast cancer cellsSTAGE OF DEVELOPMENT:• Preclinical PATENT STATUS:• Patent application in preparationCONTACT INFO:Paul Hippenmeyer, Sr. Licensing & Business Development AssociateOffice of Technology Management and Industry Relations Email: hippenmeyerp@missouri.edu Phone: 573-882-0470

*Principal Investigator

Name: Salman Hyder, Zalk Missouri Professor and Dalton Investigator

Department:

Name: Yayun Liang, Dalton Investigator and Research Assistant Professor

Department:

Country/Region

USA